An EGFR-targeted chitosan NP was created to silence the Mad2 gene using small interfering RNAs (siRNAs) in patients with A549 cell line NSCLC (epithelial carcinoma derived from a 58-year-old male patient, known to be KRAS mutant and EGFR wild type). The gene discussed is EGFR; the disease is carcinoma.